ProKidney Announces Two Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2025
Rhea-AI Summary
ProKidney (Nasdaq: PROK) will present two posters at the American Society of Nephrology Kidney Week 2025 in Houston, Nov 6–9, 2025. One is a late‑breaking poster reporting Phase 2 REGEN‑007 study results: "Renal Autologous Cell Therapy in Diabetes and CKD" (Session: Late‑Breaking Science Posters, Nov 6, 10:00 AM–12:00 PM CST, Board #TH‑PO1203). The second poster covers the inflammatory profile of the cell therapy candidate rilparencel (Session: Development, Stem Cells, and Regenerative Medicine, Nov 6, 10:00 AM–12:00 PM CST, Board #TH‑PO0575).
Copies of both posters will be available on the company website after the event and abstracts are listed on the ASN Kidney Week program site.
Positive
- None.
Negative
- None.
News Market Reaction 9 Alerts
On the day this news was published, PROK gained 11.45%, reflecting a significant positive market reaction. Our momentum scanner triggered 9 alerts that day, indicating moderate trading interest and price volatility. The stock closed at $3.31 on that trading session. This price movement added approximately $100M to the company's valuation, bringing the market cap to $973M at that time.
Data tracked by StockTitan Argus on the day of publication.
WINSTON-SALEM, N.C., Oct. 20, 2025 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that the Company will present two posters, including a late-breaking poster on the Phase 2 REGEN-007 study results, at the upcoming American Society of Nephrology’s (ASN) Kidney Week being held from November 6-9, 2025, in Houston, TX.
The titles for the accepted abstracts are provided below and accessible online at: https://www.asn-online.org/education/kidneyweek/2025/program-search-abstract.aspx
Late-Breaking Poster Presentation
Renal Autologous Cell Therapy in Diabetes and CKD (Phase 2 REGEN-007 Study Results)
Session Title: Late-Breaking Science Posters [LB-PO]
Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO1203
Other Poster Presentation
Cell-Specific Inflammatory Profile Characterization of the Cell Therapy Candidate Rilparencel
Session Title: Development, Stem Cells, and Regenerative Medicine [PO0600]
Session Date, Time: November 6, 2025 from 10:00 AM to 12:00 PM CST
Poster Board #: TH-PO0575
Following the event, a copy of the poster presentations will be available on the Company’s website at: https://prokidney.com/our-technology/publications/
Additional information on ASN Kidney Week 2025 can be accessed online at:
https://www.asn-online.org/education/kidneyweek
About ProKidney Corp.
ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cellular therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.
ProKidney Contact
Ethan Holdaway
Ethan.Holdaway@prokidney.com
Media Contact
Audra Friis
audrafriis@sambrown.com
Investor Relations Contact
Daniel Ferry
Daniel@lifesciadvisors.com
FAQ
When will ProKidney (PROK) present the Phase 2 REGEN-007 results at ASN Kidney Week 2025?
What is the title of ProKidney's late-breaking poster at ASN Kidney Week 2025?
When and where is ASN Kidney Week 2025 where PROK will present?
What other ProKidney poster will be presented and when is it scheduled?
Where can investors access ProKidney's poster presentations after ASN Kidney Week 2025?
Where can I find the ASN Kidney Week 2025 abstracts for ProKidney (PROK)?
